Outset Medical (NASDAQ:OM) CEO Sells $60,385.28 in Stock

Outset Medical, Inc. (NASDAQ:OM) CEO Leslie Trigg sold 11,794 shares of the firm’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $5.12, for a total value of $60,385.28. Following the transaction, the chief executive officer owned 107,823 shares in the company, valued at $552,053.76. The trade was a 9.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Leslie Trigg also recently made the following trade(s):

• On Wednesday, January 21st, Leslie Trigg sold 2,120 shares of Outset Medical stock. The stock was sold at an average price of $5.05, for a total transaction of $10,706.00.
• On Wednesday, January 7th, Leslie Trigg sold 1,795 shares of Outset Medical stock. The stock was sold at an average price of $4.27, for a total transaction of $7,664.65.
• On Monday, November 17th, Leslie Trigg sold 916 shares of Outset Medical stock. The stock was sold at an average price of $4.60, for a total transaction of $4,213.60.

Outset Medical Price Performance

OM traded up $0.15 during trading on Wednesday, reaching $5.20. 256,678 shares of the company’s stock were exchanged, compared to its average volume of 1,737,004. The company’s fifty day simple moving average is $4.34 and its 200-day simple moving average is $11.07. Outset Medical, Inc. has a 1 year low of $3.10 and a 1 year high of $21.98. The company has a debt-to-equity ratio of 0.69, a quick ratio of 5.77 and a current ratio of 7.09.

Analyst Ratings Changes

A number of research firms recently issued reports on OM. Royal Bank Of Canada reissued a “sector perform” rating and issued a $7.00 price target on shares of Outset Medical in a research note on Wednesday, December 17th. Wall Street Zen lowered shares of Outset Medical from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. Weiss Ratings reissued a “sell (e+)” rating on shares of Outset Medical in a research note on Monday, December 29th. BTIG Research reaffirmed a “buy” rating and issued a $17.00 price target on shares of Outset Medical in a research note on Tuesday, December 16th. Finally, Stifel Nicolaus lowered their price objective on Outset Medical from $14.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, January 7th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $10.67.

Hedge Funds Weigh In On Outset Medical

A number of institutional investors have recently bought and sold shares of OM. Alyeska Investment Group L.P. increased its holdings in shares of Outset Medical by 10.2% during the 3rd quarter. Alyeska Investment Group L.P. now owns 1,614,582 shares of the company’s stock worth $22,798,000 after buying an additional 150,000 shares during the last quarter. Assenagon Asset Management S.A. increased its stake in Outset Medical by 34.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 508,414 shares of the company’s stock worth $1,886,000 after acquiring an additional 131,381 shares during the last quarter. Pura Vida Investments LLC raised its position in Outset Medical by 8,482.4% in the second quarter. Pura Vida Investments LLC now owns 429,120 shares of the company’s stock valued at $8,243,000 after purchasing an additional 424,120 shares during the period. Millennium Management LLC raised its position in Outset Medical by 165.8% in the third quarter. Millennium Management LLC now owns 421,409 shares of the company’s stock valued at $5,950,000 after purchasing an additional 262,874 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Outset Medical by 955.9% in the 2nd quarter. Geode Capital Management LLC now owns 415,552 shares of the company’s stock valued at $7,984,000 after purchasing an additional 376,196 shares during the last quarter.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.